May 22, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Breast Cancer

» Advanced search

Paper of the Month - Volume 24 Issue 1

Please login to access this article in full. Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


1 ratings / 4 average

Treatment – Radiotherapy

Shah C, Vicini F, Keisch M et al.

William Beaumont Hospital, Royal Oak, MI, USA.

Cancer 2012 Jan 17; Epub ahead of print.

Editor’s note: With >25 years of follow-up, it has been demonstrated that breast-conservation therapy (BCT) provides long-term outcomes equivalent to those achieved with mastectomy in the management of early-stage breast cancer. Although whole-breast irradiation (WBI) has been considered the standard adjuvant radiation therapy technique to date in these patients, concerns remain about its duration. Accelerated partial breast irradiation (APBI) is a relatively new technique that allows for the delivery of adjuvant radiation while shortening the treatment course to ≤1 week. Currently, ABPI can be delivered using multiple techniques, including interstitial catheters, a balloon-based catheter, and external-beam radiotherapy. With 5–10 years of follow-up, it has been demonstrated that APBI is associated with excellent clinical outcomes (Radiother Oncol 2011;100:210–4, Int J Radiat Oncol Biol Phys 2011;79:808–17).

Please login or register to continue reading this article

READER POLL

What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?

Continuation of trastuzumab with an alternative cytotoxic agent
An alternative cytotoxic agent alone
A HER1/2 tyrosine kinase inhibitor with or without cytotoxic chemotherapy
Continuation of trastuzumab with a HER1/2 tyrosine inhibitor
Other

Find us on
Facebook

Post Page On

SUBMIT AN ARTICLE

» Click here

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 22, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

CML Breast Cancer » Advanced search